The purpose of this study is to confirm the safety and efficacy of Soluble Ferric
Pyrophosphate (SFP) dialysate solution in maintaining iron delivery for erythropoiesis in
anemic adult patients with chronic kidney disease (CKD) receiving hemodialysis. Efficacy will
be measured primarily by the change from baseline in hemoglobin (Hgb).